Welcome to our dedicated page for Datameds AI news (Ticker: MEDS), a resource for investors and traders seeking the latest updates and insights on Datameds AI stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Datameds AI's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Datameds AI's position in the market.
Datavault AI (NASDAQ: DVLT) amended its definitive agreement with DataMeds AI (NASDAQ: MEDS) to expand its PharmacyChain blockchain-related technology license from pharmaceutical distribution to all unencumbered commercial healthcare, healthspan and wellness uses of Datavault AI intellectual property. The expansion is intended to bring Datavault AI’s data monetization and real‑world asset tokenization technologies into DataMEDS’ EinsteinRX platform and broader healthcare data environment, enabling patient‑controlled health data access and transaction models across pharmacy, medical, laboratory and wearable settings.
According to Datavault AI, it will receive common shares equal to about 19.9% of DataMEDS common stock, instead of preferred shares, once previously disclosed transactions with Scilex, EOS Technology Holdings and HealthBridge Advisors/HighBridge close. The share issuance, expected to be recognized as revenue upon issuance, remains subject to acquisition of two QOLPOM intellectual property portfolios and a controlling interest in Tollo Health. DataMEDS recently rebranded from Wellgistics Health, began trading under ‘MEDS’ on July 22, 2026, and plans a dividend of 50 Dream Bowl Meme Coin tokens per common share owned as of an August 7, 2026 record date, subject to its discretion.
DataMEDS AI (NASDAQ:MEDS) updated the record date for its planned distribution of the Dream Bowl 2026 Meme Coin to stockholders from July 31, 2026 to August 7, 2026. Holders of DataMEDS common stock on that date will be entitled to receive 50 Dream Bowl 2026 Meme Coins per share.
DataMEDS plans to collect stockholders’ digital wallet information to enable the crypto distribution, with the final distribution date to be set later in coordination with DataVault AI (NASDAQ:DVLT). DataMEDS reports 2,847,198 common shares outstanding, of which stockholders holding about 1,533,930 shares have agreed to 90‑day lock‑ups. The company highlights 919,465 common shares currently available for trading through DTCC and notes there are no convertible debt or preferred securities outstanding, but 80,826 cash warrants exercisable at $35.00 per share.
DataMEDS AI (NASDAQ: MEDS), a Health IT company formerly known as Wellgistics Health (NASDAQ: WGRX), has completed its stock trading symbol change to “MEDS” on the NASDAQ Capital Market, effective at the start of trading on July 22, 2026, finalizing its corporate rebranding.
DataMEDS focuses on integrating its AI platform EinsteinRx™ and blockchain-enabled PharmacyChain™ into the Health Lives Here app and Tollo Health to support data-driven healthcare, including GLP‑1-associated muscle loss and Long COVID. The company reports 2,847,198 common shares outstanding, with approximately 1,533,930 shares under 90‑day lock-up agreements. There are 919,465 common shares currently in DTCC and available for trading, no debt or preferred securities convertible into common shares, and 80,826 cash warrants outstanding with a fixed exercise price of $35.00 per share.